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ABSTRACT
Objective Clinical outcomes of HIV-infected children on 
antiretroviral treatment (ART) in a decentralised, nurse/
counsellor-led programme.
Design Clinical cohort.
Setting KwaZulu-Natal, South Africa.
Patients HIV-infected children aged ≤15 years on ART, 
June 2004–2008.
Main outcome measures Survival according to 
baseline characteristics including age, WHO clinical 
stage, haemoglobin and CD4%, was assessed in 
Kaplan–Meier analyses. Hazard ratios for mortality were 
estimated using Cox proportional hazards regression and 
changes in laboratory parameters and weight-for-age z 
scores after 6–12 months’ treatment were calculated.
Results 477 HIV-infected children began ART at a 
median age of 74 months (range 4–180), median CD4 
count (CD4%) of 433 cells/mm3 (17%) and median 
HIV viral load of log 4.2 copies/ml; 105 (22%) were on 
treatment for tuberculosis and 317 (76.6%) were WHO 
stage 3/4. There were signifi cant increases after ART 
initiation in CD4% (17% vs 22%; p<0.001), haemoglobin 
(9.9 vs 11.7 g/l; p≤0.001) and albumin (30 vs 36 g/l; 
p≤0.001). 32 (6.7%) children died over 732 child-years 
of follow-up (43.7 deaths/1000 child-years; 95% CI 
32.7 to 58.2), 17 (53.1%) within 90 days of treatment 
initiation; median age of death was 84 (IQR 10–181) 
months. Children with baseline haemoglobin ≤8 g/l 
were more likely to die (adjusted HR 4.5; 95% CI 1.6 to 
12.3), as were those aged <18 months compared with 
>60 months (adjusted HR 3.2; 95% CI 1.2 to 9.1).
Conclusions Good clinical outcomes in HIV-infected 
children on ART are possible in a rural, decentralised 
service. Few young children are on ART, highlighting the 
urgent need to identify HIV-exposed infants.
INTRODUCTION
The mortality and morbidity of HIV-infected chil-
dren in developed countries has improved con-
siderably with antiretroviral treatment (ART).1 
Children in developing countries show simi-
lar improvements in health and survival when 
given ART, despite a restricted choice of drug 
regimens.2–5 However, the proportion of children 
with access to ART remains unacceptably low.6 7 
Of the estimated 780 000 children under 15 years 
of age eligible for ART globally, only 10% were 
receiving treatment by the end of 2007, and subse-
quent progress has been painfully slow.7 Further, 
early treatment of infants with ART results in 
substantially improved survival.8 9 This in turn 
relies critically on early diagnosis of HIV-exposed 
infants and appropriate referral from well-func-
tioning prevention of mother-to-child transmis-
sion (PMTCT) programmes.6 7 10
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Problems in providing wide-scale ART in sub-
Saharan Africa, particularly in rural areas, include 
lack of health personnel, difﬁ culties with trans-
port and delivery of drugs to health facilities, lack 
of diagnostic facilities, and limited and costly 
paediatric drug formulations compounded by the 
production of syrups requiring refrigeration rather 
than difﬁ cult-to-dose tablets, and no affordable 
ﬁ xed-dose paediatric drug combinations.4 11–14 
Evaluation of the few existing programmes is hin-
dered by a lack of functioning monitoring systems 
to quantify deaths and attrition due to loss to fol-
low-up, which may be substantial.15
We add to the knowledge base by reporting on 
the clinical and virological outcomes of children 
on ART in a decentralised, nurse- and counsellor-
led programme in rural South Africa.
METHODS
The setting
Hlabisa sub-district, situated in rural northern 
KwaZulu-Natal, covers 3729 km2, with a popu-
lation of approximately 220 000. KwaZulu-Natal 
has one of the highest HIV burdens in the world, 
with a peak prevalence of 27% in females aged 
15–49, and 13.5% in males aged 15–54,13 and 
a prevalence of around 38% among pregnant 
What is already known on this topic
▶  There has been rapid scale-up of HIV 
treatment programmes in Africa, home to 
most HIV-infected children globally.
▶  HIV-infected children in developing countries 
given antiretroviral therapy (ART) show 
similar improvements in health and survival 
to children in the developed world, although 
experience with paediatric ART in resource-
limited settings is limited.
What this study adds
▶  Good clinical and virological outcomes 
of children on ART are possible in a 
decentralised, nurse/counsellor-led 
programme, in a rural resource-limited 
setting.
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including full blood count, liver function tests, CD4 counts 
and viral loads.
DoH drug regimens24 are followed, with ﬁ rst-line treatment 
consisting of two nucleoside reverse transcriptase inhibitors 
(stavudine and lamivudine) plus one non-nucleoside reverse 
transcriptase inhibitor (efavirenz) for those aged over 3 years, 
or a protease inhibitor (lopinavir/ritonavir) for those aged 
under 3 years. Second-line treatment includes zidovudine, 
didanosine and either nevirapine or efavirenz for children aged 
less than 3 years, and lopinavir/ritonavir for those over 3 years. 
The programme does not have access to resistance testing.
Medicine is collected monthly; children failing to collect 
medicine at scheduled visits are considered to have defaulted 
treatment and attempts are made to trace the patient by phone 
or home visit by a nurse tracker. Children who have not col-
lected their medicine for 3 months, despite attempts to trace 
them, and who are not known to have died or transferred out 
of the programme, are regarded as lost to follow-up from the 
last known contact date at the clinic.
A home-based care programme, consisting of three nurses 
and 470 community volunteers, trained in ﬁ rst aid, nutrition 
and ART adherence, provide additional care, at home, for chil-
dren requiring extra support.
Data management
Patient data are stored in paper-based records at clinics. The 
baseline data of all children initiated on ART, and limited clinic 
follow-up details, were collected from the clinics monthly by 
a monitoring and evaluation team, and entered into a secure 
electronic database with restricted access (C Newell, personal 
communication, May 2009).
Statistical analysis
Eligibility criteria for inclusion in the analyses included all 
those aged ≤15 years who were started on ART by the end 
of June 2008; this cut-off date was chosen to allow at least 6 
months of follow-up on ART for all children. Continuous vari-
ables were compared using t tests, and categorical variables 
using Pearson’s χ2 tests. Survival by baseline characteristics 
including age, WHO clinical stage, haemoglobin and CD4%, 
was assessed in Kaplan–Meier analyses.26 Hazard ratios (HR) 
for mortality were estimated using Cox proportional hazards 
regression.27 Weights were plotted against US Centers for 
Disease Control and Prevention charts,28 using Epi Info 2000 
to determine weight-for-age z scores (WAZ). CDC charts 
were used in preference to the WHO reference 2007 package29 
because the latter computed WAZ scores up to age 10 years 
only, while the former goes up to age 20 years, which included 
our age limit (<16 years).
We calculated the mortality and lost to follow-up rates of 
children on ART, before and after 90 days of therapy, with 
exact 95% conﬁ dence limits; time periods were in line with 
women.16 Unemployment is high and families with no income 
rely on social grants.17
Healthcare
The health infrastructure is typical of many other rural health 
districts in South Africa, consisting of 16 primary healthcare 
clinics, two mobile clinic facilities and one 296-bed district 
hospital. Nurses run the busy clinics, with 95% of pregnant 
women attending at least one antenatal clinic visit18 and up 
to 80% of children achieving full primary vaccination.19 
Individuals travel an average of 4.72 km to their nearest clinic, 
with a maximum distance of 13.2 km.20
Hlabisa HIV treatment and care programme
The Hlabisa HIV treatment and care programme, which ﬁ rst 
started treating patients in June 2004, is a partnership between 
the Department of Health (DoH) and the Africa Centre for 
Health and Population Studies (www.africacentre.ac.za), 
with additional funding provided by PEPFAR. The service is 
decentralised; patients access free care at their nearest primary 
healthcare clinic, where nurses and counsellors (lay staff who 
receive standardised training on issues including HIV counsel-
ling and testing, HIV treatment and adherence, and drug side-
effects) are based. Physicians visit all clinics to initiate ART 
and follow up on medical problems. A few patients start ART 
as in-patients in the local hospital. Access to private medical 
care is limited.21
Children enter the programme by a number of routes: 
through the DoH prevention of mother-to-child transmission 
(PMTCT) programme implemented in 2001, a tuberculosis (TB) 
programme where HIV testing of all patients is encouraged,22 
testing and referral after illness, HIV testing if other family 
members are already on treatment, or transfer into the pro-
gramme of children already on ART. Eligibility, using a combi-
nation of immunological and clinical criteria, is assessed using 
provincial DoH paediatric guidelines, ﬁ rst published in 200423 
and revised in March 2008,24 in line with WHO guidelines,14 
and reﬂ ecting evidence that early treatment in infants results 
in better clinical outcomes8 (table 1).
Children undergo clinical staging, are screened for pulmo-
nary tuberculosis (based on history, examination and chest 
x-ray), which is highly prevalent in the area,25 and opportu-
nistic infections are treated. Baseline blood samples are taken 
(CD4, viral load, full blood count, creatinine and liver func-
tion tests); samples for viral load measurement are sent to the 
referral hospital 75 km away, while all other tests are carried 
out at the local hospital. Children eligible for treatment have 
a named caregiver who undergoes three educational training 
sessions, conducted by HIV counsellors, before treatment is 
started. Children are followed up by nurses and counsellors at 
monthly visits, with physician appointments when clinically 
indicated. Laboratory parameters are repeated 6-monthly, 
Table 1 Clinical criteria for eligibility for antiretroviral therapy in children, KwaZulu-Natal, South Africa24
Confi rmation of diagnosis of HIV infection AND
Recurrent hospitalisations OR symptomatic children
>2 admissions per year for HIV complications 
OR prolonged hospitalisation for HIV 
(>4 weeks)
<1-year of age 1–5 years of age >5 years of age
WHO stage 2, 3 and 4
OR
CD4 ≤35%
OR
Absolute CD4 count <1500 cells/mm3
WHO stage 3 and 4
OR
CD4 ≤ 20% 
WHO stage 3 and 4
OR
CD4 <15%
OR
Absolute CD4 <200 cells/mm3
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previously published reports.2 30 Reported overall mortality 
considers active patients only, and excludes children who 
are lost to follow-up from the programme. However, upper 
mortality estimates are also presented assuming all chil-
dren with advanced disease (WHO clinical stage 3 or 4) who 
were lost to follow-up have died, and also, separately, that 
all children lost to follow-up have died. For the mortality 
and attrition analyses, we generated a proportional hazards 
model for all children because our numbers were too small 
to allow stratiﬁ cation by different age groups. Factors in the 
univariate analysis found to be signiﬁ cant at p<0.05 were 
included in the multivariable proportional hazards regres-
sion model.
We dichotomised haemoglobin concentration at <8.0 g/l or 
≥8.0 g/l, albumin at ≤27 g/l or >27 g/l, WAZ at >−1, >−2 to 
−1, and <−2, WHO staging at 1 and 2, or 3 and 4, and CD4% at 
≥20, 10 to <20, and <10. All analyses were performed in Stata 
(v 9.2; Stata Corporation, College Station, Texas, USA).
Ethics
Individual informed written consent was obtained from all 
participants in the programme to allow use of anonymised 
routine clinical data for research. Ethics approval was 
obtained from the Biomedical Research Ethics Committee of 
the University of KwaZulu-Natal and Research Ofﬁ ce of the 
KwaZulu-Natal DoH.
RESULTS
Between 1 June 2004 and 30 June 2008, 477 HIV-1 infected 
children were on ART; 68 of these (14.3%) transferred into the 
programme already on treatment. By 1 July 2008, 415 children 
(87%) were alive and active in the programme, 12 (2.5%) had 
transferred out of the programme and 50 (10.5%) had either 
died or were reported lost to follow-up (32 (6.7%) died, 18 
(3.8%) were lost to follow-up).
Cohort characteristics at initiation
Children were relatively old at treatment initiation (median 
age 74 months) and only 58 (12.2%) children were <18 months 
of age (table 2A). The majority were in late stage clinical dis-
ease, almost half were under-nourished with a weight-for-age 
(WAZ) of less than −2 z scores, and a quarter had tuberculosis 
at initiation.
Virological and immunological responses to  
treatment (table 2B)
Overall, 447 (94%) children were still active in the programme 
after at least 6 months of treatment. In 310 (65%) children with 
Table 2A Characteristics of children prior to antiretroviral therapy, rural KwaZulu-Natal (June 2004–June 2008)
Variable
All ages Age <18 months Age 18–59 months Age ≥60 months
(N=477) (N=58) (N=132) (N=287)
Age, median (range), months 74 (4–180) 13 (4–17) 36 (18–59) 107 (60–180)
Female, n (%) 227 (47.6%) 28 (49.2%) 64 (48.1%) 135 (47.0%)
Weight-for-age z score 
Median (IQR) –1.8 (–2.5 to –0.8) –1.8 (–2.8 to –0.9) –1.5 (–2.5 to –0.5) –1.9 (–2.5 to –0.9)
≤–2, n (%) 178 (37.3%) 21 (36.2%) 40 (30.3%) 117 (40.8%)
>–2 to –1, n (%) 115 (24.1%) 12 (20.7%) 32 (24.2%) 71 (24.7%)
>–1, n (%) 116 (24.3%) 11 (19.0%) 40 (30.3%) 65 (22.7%)
Missing, n (%) 68 (14.3%) 14 (24.1%) 20 (15.2%) 34 (11.8%)
CD4 cell per cent
Median (IQR) 17 (11–26) 19 (11–28) 19 (12–28) 16 (10–25)
Missing, n (%) 178 (37.3%) 19 (32.8%) 53 (40.2%) 106 (36.9%)
CD4 cell count
Median (IQR) 433 (224–747) 766 (464–1130) 606 (307–1010) 361 (164–581)
Missing, n (%) 173 (36.2%) 19 (32.8%) 54 (40.9%) 100 (34.8%)
Log viral load
Median (IQR) 4.2 (3.2–5.2) 4.9 (3.4–5.9) 4.8 (3.8–5.8) 3.9 (2.9–4.7)
Missing, n (%) 293 (61.4%) 39 (67.2%) 85 (64.4%) 169 (58.9%)
Haemoglobin
Median (IQR) 9.9 (8.9–10.9) 9.5 (8.4–10.4) 9.5 (8.5–10.4) 10.1 (9.2–11.1)
Missing, n (%) 105 (22.0%) 22 (37.9%) 32 (24.2%) 51 (17.8%)
Albumin
Median (IQR) 30 (25–34) 30 (25–35) 29.5 (24–35) 29.5 (25–34)
Missing, n (%) 100 (20.9%) 23 (39.6%) 30 (22.7%) 47 (16.4%)
Tuberculosis at initiation
Yes, n (%) 105 (22.0%) 15 (28.9%) 30 (22.7%) 17 (5.7%)
No, n (%) 343 (71.9%) 36 (62.1%) 97 (73.5%) 210 (73.2%)
Missing, n (%) 29 (6.1%) 7 (12.0%) 5 (3.8%) 227 (79.1%)
WHO stage
1 or 2, n (%) 97 (20.3%) 15 (25.9%) 19 (14.4%) 63 (21.9%)
3 or 4, n (%) 317 (66.5%) 37 (63.8%) 97 (73.5%) 183 (63.8%)
Missing, n (%) 63 (13.2%) 6 (10.3%) 16 (12.1%) 41 (14.3%)
IQR, interquartile range; WHO, World Health Organization.
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a CD4% result available at 6–12 months after treatment ini-
tiation, the median CD4% increased by 29% of the original, 
from 17% pre-initiation to 22% 6–12 months post-initiation 
(p<0.001). Similarly, a substantial increase in absolute CD4 
count of 20% was seen among the 315 (66%) children with 
a result, from 433 cells/μl pre-initiation to 519 cells/μl at 6–12 
months post-initiation. Haemoglobin and albumin values sig-
niﬁ cantly increased from 9.9 to 11.7 g/l (p≤0.001) and from 30 
to 36 g/l (p≤0.001), respectively (table 2B). In the less than half 
of the cohort (n=184) for whom this information was avail-
able, median viral load at initiation was 153 006 copies/ml; 142 
(73.5%) of 193 children who had a viral load after 6–12 months 
of treatment showed viral load suppression (<25 copies/ml).
Survival outcomes
Of 477 children, 32 (6.7%) died over 732 child-years of fol-
low-up (table 3A). Children died at a median age of 84 (inter-
quartile range (IQR) 10 to 181) months, and compared to those 
who survived, had a lower median WAZ score (–2.8 (IQR 
–8.0 to –1.0) vs 1.3 (–7.7 to –1.0); p=0.026) and lower baseline 
haemoglobin (8.6 (IQR 5.4 to 11.3) g/l vs 10.0 (4.1 to 24.4) g/l; 
p=0.007), were more likely to be WHO clinical stage 3 or 4 
(92% vs 74%; p=0.040) and had greater immunosuppression 
(CD4% 9% (IQR 2% to 23%) vs 18% (IQR 1% to 58%); 
p<0.001).
Most deaths occurred soon after treatment initiation; of 
the 32 children who died, 17 (53.1%) died within 90 days of 
starting ART, while the other15 died after the ﬁ rst 3 months. 
Similar trends were observed across all age groups (table 3A).
Differences in mortality, which persisted for years, were 
observed by haemoglobin levels, age, WHO clinical stage and 
CD4% at initiation (ﬁ gure 1). Allowing for sex, WAZ, CD4%, 
haemoglobin, albumin, WHO stage, tuberculosis at initiation 
and age, the risk of dying was signiﬁ cantly increased with a 
haemoglobin <8 and age <18 months. Risk was also higher for 
malnourished (WAZ ≤–2) and immunosuppressed (CD4% 
<10) children, increasing with successively lower WAZ and 
lower CD4%, but this did not reach statistical signiﬁ cance 
(table 4; ﬁ gure 1).
Loss to follow-up
Of 477 children started on ART, 18 (3.8%) were lost to follow-up 
(24.6 per 1000 child-years; table 3B). No signiﬁ cant differences 
in attrition were observed in the ﬁ rst 3 months of treatment 
compared to later in therapy. Multivariably, allowing for the 
same factors in table 4, the hazard of loss to follow-up was 
Table 3A Mortality in children receiving antiretroviral therapy, rural KwaZulu-Natal (June 2004–June 2008)
 No Deaths (n) Follow-up (child-years)
Mortality ratio/1000 
child-years (95% CI)
Overall 477 32 732.13 43.7 (32.7 to 58.2)
Within 90 days 17 112.39 151.3 (130.4 to 174.8)
After 90 days 15 618.81 24.2 (16.3 to 35.7)
Children aged <18 months 59 6 78.7 76.2 (61.3 to 94.3)
Within 90 days 2 13.42 149.0 (128.3 to 172.4)
After 90 days 4 65.27 61.3 (48.0 to 77.9)
Children aged 18–59 months 131 8 192.2 41.6 (30.9 to 55.8)
Within 90 days 7 31.2 224.4 (199.6 to 251.3)
After 90 days 1 161 6.2 (2.9 to 13.3)
Children aged ≥60 months 287 18 461.3 39.0 (28.7 to 52.9)
Within 90 days 8 67.8 117.9 (99.4 to 139.4)
After 90 days  10 392.5 25.5 (17.4 to 37.2)
Table 2B Laboratory markers of children 12 months after initiation of antiretroviral therapy, rural  KwaZulu-Natal 
(June 2004–June 2008)
 Variable
All ages Age <18 months Age 18–59 months Age ≥60 months
(N=447) (N=52) (N=123) (N=272)
CD4 cell per cent
Median (IQR) 22 (15–28) 26 (20–30) 24 (17–30) 20 (14–27)
Missing, n (%) 137 (30.6%) 26 (50.0%) 36 (29.2%) 77 (28.3%)
CD4 cell count
Median (IQR) 519 (347–835) 1077 (712–1343) 696 (422–1068) 471 (15–1591)
Missing, n (%) 132 (29.5%) 26 (50.0%) 34 (27.6%) 74 (27.2%)
Log viral load
Median (IQR) 3.3 (2.5–4.2) 4.7 (3.4–6.2)   3.1 (2.5–3.7)    3.3 (2.4–4.1)
Missing, n (%) 254 (56.8%) 33 (63.5%) 72 (58.5%) 149 (54.8%)
Haemoglobin
Median (IQR) 11.7 (10.8–12.3) 10.7 (10.5–11.2)   11.1 (10.7–12.1)     11.8 (10.9–12.5)
Missing, n (%) 245 (54.8%) 41 (97.6%) 72 (58.5%) 133 (48.9%)
Albumin
Median (IQR) 36 (32–39) 35 (30–36) 37 (33–39) 36 (33–38)
Missing, n (%) 262 (58.6%) 39 (75.0%) 67 (54.5%) 127 (46.7%)
IQR, interquartile range; WHO, World Health Organization.
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associated with HIV stage and CD4%: compared with chil-
dren in clinical stage 1/2, those in stage 3/4 were more likely 
to be lost to follow-up (adjusted HR 1.40; 95% CI 1.08 to 1.83; 
p=0.030); compared to children with a CD4% >20%, those 
with a depleted CD4% were more likely to be lost to follow-up 
(adjusted HR 1.64; 95% CI 1.17 to 23.1) (data not shown).
Children with more advanced disease (WHO clinical stage 
3/4) had a threefold increased risk of mortality (table 4). 
Assuming that all children with advanced disease who were 
lost to follow-up had died, the upper mortality estimate in this 
rural cohort would have been 60.1 (rather than 43.7) per 1000 
child-years; while assuming that all those lost to follow-up 
had died, the upper mortality estimate would have been 68.3 
per 1000 child-years.
DISCUSSION
We report good clinical outcomes and low levels of loss to 
follow-up in an HIV treatment and care programme in rural 
Table 3B Attrition in children receiving antiretroviral therapy in rural KwaZulu-Natal 
(June 2004–June 2008)
 No. Attrition (n) Follow-up (child-years)
Attrition rate/1000 
child-years (95% CI)
Overall 477 18 732.13 24.6 (16.7 to 36.2)
Within 90 days 3 112.39 26.7 (18.4 to 38.6)
After 90 days 15 618.81 24.2 (16.3 to 35.7)
Children aged <18 months  59 4 78.7 50.8 (38.8 to 66.2)
Within 90 days 1 13.42 74.5 (59.8 to 92.5)
After 90 days 3 65.27 46.0 (34.6 to 60.7)
Children aged 18–59 months 131 5 192.2 26.0 (17.8 to 37.8)
Within 90 days 0 31.2  0
After 90 days 5 161 31.1 (22.0 to 43.8)
Children aged ≥60 months 287 9 461.3 19.5 (12.6 to 30.1)
Within 90 days 2 67.8 29.5 (20.7 to 41.9)
After 90 days  7 392.5 17.8 (11.3 to 28.0)
Figure 1 Mortality in children receiving antiretroviral therapy by (A) haemoglobin concentration, (B) age, (C) WHO clinical stage and (D) CD4 cell 
percentage.
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our results suggest the enormous problems in identifying 
infected infants, and highlight the urgency of strengthening 
PMTCT programmes to reduce the cumulative loss of individ-
uals in the PMTCT cascade, from initial counselling of preg-
nant women to ﬁ nal diagnosis of infants who have ceased all 
breast feeding.37
Given the late presentation of children for treatment, it is not 
surprising that the majority were in WHO stage 3/4, a quar-
ter already had tuberculosis, a third demonstrated moderate 
to severe malnutrition with a weight-for-age z score below −2, 
and median haemoglobin levels were low. Anaemia, a common 
complication of paediatric HIV infection, has previously been 
associated with disease progression and death.15 38 The aetiol-
ogy is considered to be insufﬁ cient erythropoietin, and thus 
difﬁ cult to manage in resource-poor settings where available 
treatment consists of blood transfusions and iron supplements, 
for which there is limited evidence of efﬁ cacy.38 Severe anae-
mia (haemoglobin <8 g/l) was associated with an increased 
mortality risk in our cohort, and underlines the importance of 
earlier diagnosis while children are clinically well. The large 
proportion of children presenting with malnutrition and TB 
also illustrates the need for integration of HIV programmes 
with other care at primary healthcare level, as opposed to the 
numerous vertical programmes frequently observed.21 22 In 
South Africa, adding to the emerging literature on ART in chil-
dren in developing countries. A unique feature of this cohort is 
the decentralised model of care. The mean distance travelled 
by any individual in the population to their nearest clinic is 
4.72 km (maximum 13.2 km)20 with a median travel time of 
81 min.31 Travel time to the local hospital is double this (170 
min),31 which is more costly to the patient and a potential bar-
rier to regular clinical follow-up,32 in addition to overburden-
ing the referral centre.
With the scale-up of ART programmes in sub-Saharan 
Africa, the issue of sustainability of rapidly expanding pro-
grammes is of concern.33 Task shifting, with a move away 
from physician-led diagnosis and management, has been 
discussed,34 but experience in paediatric ART programmes is 
limited. Although physicians initiate ART in our programme, 
follow-up is largely carried out by nurses and counsellors, thus 
providing information about clinical outcomes in a devolved 
service.
In line with other reports from sub-Saharan Africa,15 35 chil-
dren were relatively old at treatment initiation, with only 58 
(12.1%) children commencing treatment under the age of 18 
months. PCR tests36 using dried blood spots for infants aged 6 
weeks are the standard of care in South Africa, with in princi-
ple the possibility of HIV diagnosis by age 3 months. However, 
Table 4 Factors associated with mortality in children receiving antiretroviral therapy
Crude Adjusted
     No. HR (95% CI) p Value aHR (95% CI) p Value
Sex
Female 227 1.00 1.00
Male 250 0.88 (0.44 to 1.77) 0.726 0.64 (0.29 to 1.42) 0.296
Weight-for-age
>−1 116 1.00 1.00
>−2 to −1 115 6.14 (0.74 to 50.99) 0.093 3.88 (0.45 to 33.62) 0.218
≤−2 178 12.52 (1.67 to 93.80) 0.014 5.95 (0.74 to 47.45) 0.092
Missing 68 12.68 (1.56 to 103.04) 0.018 3.95 (0.42 to 37.20) 0.230
CD4 cell per cent
≥20 134 1.00 1.00
10 to <20 104 1.46 (0.29 to 7.25) 0.643 1.17 (0.23 to 5.94) 0.852
<10 61 5.07 (1.27 to 20.33) 0.022 3.61 (0.87 to 14.97) 0.076
Missing 178 5.75 (1.71 to 19.38) 0.005 3.52 (0.97 to 12.69) 0.054
Haemoglobin
≥8 341 1.00 1.00
<8 31 6.53 (2.82 to 15.15) <0.001 4.49 (1.63 to 12.33) 0.004
Missing 105 1.45 (0.59 to 3.49) 0.413 1.12 (0.37 to 3.38) 0.834
Albumin
>27 232 1.00 1.00
≤27 145 3.63 (1.63 to 8.09) 0.002 1.89 (0.79 to 4.51) 0.147
Missing 100 1.41 (0.47 to 4.21) 0.538 0.71 (0.18 to 2.80) 0.628
WHO staging
1 and 2 97 1.00 1.00
3 and 4 317 4.07 (0.96 to 17.25) 0.057 3.31 (0.67 to 16.18) 0.139
Missing 63 5.47 (1.10 to 27.12) 0.037 5.49 (0.92 to 32.76) 0.062
TB initiation
No 343 1.00 1.00
Yes 105 0.65 (0.25 to 1.70) 0.384 0.60 (0.22 to 1.64) 0.323
Missing 29 0.43 (0.06 to 3.17) 0.408 0.61 (0.07 to 5.07) 0.646
Age group
≥60 months 287 1.00  1.00  
<18 months 58 0.51 (0.18 to 1.47) 0.213 3.24 (1.15 to 9.12) 0.026
18–59 months 132 0.49 (0.19 to 1.25) 0.141 0.93 (0.38 to 2.28) 0.869
HR, hazard ratio; aHR, adjusted hazard ratio.
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this service children receive integrated disease management, 
including for malnutrition and TB, with the same counsellors 
providing adherence support for ART and TB medication. In 
an attempt to improve services further, a family-based clinic 
operating once weekly has been established at the busiest pri-
mary healthcare centre.
Our best estimate mortality of 43.7 deaths per 1000 child-
years compares well with other cohorts from sub-Saharan 
Africa, including a large Zambian cohort2 with a mortality of 
66 deaths per 1000 child-years, which is similar to our upper 
mortality estimate, and a 2-year risk of death after ART initia-
tion of 6.9% in the KIDS-ART LINC collaboration.15 The high 
mortality in the early months after treatment initiation, in 
line with other reports,2 15 39 illustrates the need for increased 
monitoring and early identiﬁ cation of clinical problems dur-
ing this phase. Young children were at increased risk of death, 
again highlighting the need for early diagnosis before infants 
become clinically unwell, with a system allowing fast- tracking 
of those eligible for treatment.8
Surprisingly, we had extremely low rates of attrition, despite 
the decentralised model of care, rural location and high mobil-
ity of our population. This is contrary to ﬁ ndings from pooled 
data from 16 urban African sites, where attrition was high but 
mortality low.15 Each case lost to follow-up was thoroughly 
investigated to ascertain further details, in particular whether 
the child had died. Children who were immunologically 
depleted or with more advanced disease were more likely to 
be lost to follow-up. It is possible that some of the 18 children 
lost to follow-up might have died, thus increasing mortality 
but decreasing attrition rates, resulting in a very low attri-
tion rate but mortality comparable with other African sites. 
We suggest that our low attrition rates are due to accessible 
services, a patient tracking system, an integrated package of 
care minimising time spent at clinics, and the assumption that 
some children with difﬁ cult social circumstances might not 
have entered the programme at all.
Emphasis has been placed on increasing numbers of children 
on treatment globally,21 35 however, with expansion of paedi-
atric ART programmes the quality of, and retention in, care 
will become increasingly important. One of the weaknesses 
of our study is the large proportion (approximately one third) 
of children who do not have a viral load or CD4 count result 
6–12 months after treatment initiation. However, of those 
with a result, three quarters showed viral suppression, similar 
to other reports,39 but the need for constant monitoring and 
vigilance remains as cohorts mature and issues of treatment 
failure arise.
There are many challenges to sustaining a rapidly expand-
ing programme such as this. Priorities for the future include 
increasing numbers of infants on treatment, improving the 
proportion of children with documented laboratory results, 
maintaining low rates of loss to follow-up, and identifying 
and tracing children with unsuppressed viral loads in a timely 
manner. Decentralised programmes depend on the dedica-
tion of clinic-based staff, who deserve encouragement, regular 
clinical updates and feedback about the successes, not only the 
difﬁ culties, of the programme.
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